Cerebrolysin is an unusual entry in the cognitive-enhancement conversation because it is not a supplement, pill, or stimulant. It’s a prescription injectable mixture of neuroactive peptides and amino acids derived from porcine brain proteins, formulated to act “neurotrophically”—that is, to support neurons under stress and help recovery after injury.

In clinical use, it’s typically given as daily IV infusions in cycles (for example, 10–20+ days per course, sometimes repeated). In the United States it is not FDA-registered/approved for sale, while it is used in many other countries for neurological indications under medical supervision.

Because of that clinical profile, the strongest evidence comes from whether Cerebrolysin can measurably improve cognition, attention, or function when the brain is impaired—after stroke, traumatic brain injury, perioperative stress, or in dementias.

The modern literature is substantial, but it is also mixed: many studies report modest benefits on rating scales, while others show little effect on longer-term disability outcomes, and heterogeneity (different doses, time windows, and outcome measures) is a recurring limitation.

Neuroprotection Plus Neuroplasticity

Across reviews and translational studies, Cerebrolysin is commonly described as having pharmacodynamic actions that resemble endogenous neurotrophic signaling (the kinds of signals involved in neuronal survival, synaptic maintenance, and repair).

Mechanistically, authors emphasize several converging effects relevant to cognition: dampening excitotoxicity, reducing oxidative stress and inflammatory signalling, and supporting synaptic remodelling and neuroplasticity. These proposed mechanisms are consistent with why the drug is most often studied in injured or vulnerable brains, not in healthy volunteers.

Stroke Recovery

The strongest contemporary clinical signal for Cerebrolysin is in early neurological recovery after ischemic stroke, typically measured by the NIH Stroke Scale (NIHSS). A 2025 systematic review and meta-analysis of 14 randomized controlled trials (2,884 patients) reported a statistically significant advantage for Cerebrolysin on NIHSS change (mean difference +1.39 NIHSS points, 95% CI 0.53–2.25, p = 0.020).

For functional independence (modified Rankin Scale, mRS 0–2), the pooled estimate favored Cerebrolysin but did not reach significance (RR 1.31, 95% CI 0.90–1.91). Safety outcomes were broadly similar: serious adverse events RR 1.08 (95% CI 0.84–1.40) and mortality RR 0.86 (95% CI 0.68–1.09). Notably, hemorrhagic transformation was lower in the Cerebrolysin group (RR 0.55, 95% CI 0.32–0.92). (Patel et al. 2025)

That hemorrhage-related signal aligns with a more mechanistic, reperfusion-era pilot trial. In the CEREHETIS study—Cerebrolysin added to alteplase in acute ischemic stroke (Cerebrolysin 30 mL/day for 14 days; 126 treated vs 215 controls)—symptomatic hemorrhagic transformation was reduced (OR 0.248, 95% CI 0.072–0.851, p = 0.019). NIHSS at day 14 also improved (p = 0.045), but there was no difference in day-90 mRS. (Khasanova & Kalinin 2023)

A later post-hoc analysis of CEREHETIS focused on time-dependent hemorrhage risk in higher-risk subgroups, again reporting reduced symptomatic hemorrhagic transformation (e.g., HR 0.245, 95% CI 0.072–0.837, p = 0.020 in high-risk patients). The authors frame this as hypothesis-generating rather than definitive clinical guidance. (Kalinin et al. 2025)

Interestingly, European neurorehabilitation guidance documents have discussed Cerebrolysin as a pharmacological add-on in early motor rehabilitation after ischemic stroke (for example, a suggested regimen of 30 mL/day IV for ≥10 days in the cited guideline summary). (Mureșanu et al. 2022)

Traumatic brain injury

In traumatic brain injury (TBI), the picture is similar: many small or heterogeneous studies, with some pooled benefits on broad neurological scales. A 2023 systematic review and meta-analysis in Brain Sciences included 10 clinical studies (total 8,749 patients, mixing prospective and retrospective designs).

The authors reported an improvement on the Glasgow Outcome Scale (GOS) at endpoint (difference in means 0.422, 95% CI 0.262–0.581, p < 0.001), while effects on length of stay were not significant. For mortality, their pooled analysis did not show a statistically significant difference (reported Z ≈ −1.596, p ≈ 0.111), and the paper repeatedly notes high heterogeneity in several endpoints. (Jarosz et al. 2023)

From a cognitive-enhancement perspective, TBI is a setting where attention, processing speed, and executive function are often impaired; several underlying trials in this literature use neuropsychological tests (e.g., Stroop-type tasks) alongside global scales.

But the biggest caution is that pooled “average” effects in TBI can be distorted by differences in injury severity, timing of treatment initiation (hours vs months), and co-interventions.

Alzheimer’s Disease

Cerebrolysin has also been studied in dementias, where cognition is the primary endpoint rather than a secondary recovery measure. In a meta-analysis of six randomized, double-blind, placebo-controlled trials in mild-to-moderate Alzheimer’s disease, Cerebrolysin (30 mL/day) showed statistically significant advantages at 4 weeks in cognitive function (standardized mean difference −0.40, 95% CI −0.66 to −0.13, p = 0.0031) and in global clinical change (odds ratio 3.32, 95% CI 1.20–9.21, p = 0.0212).

Effects at 6 months were more variable for cognition (SMD −0.37, 95% CI −0.90 to 0.16, p = 0.1710) but remained significant for global clinical change (OR 4.98, 95% CI 1.37–18.13, p = 0.0150). Safety outcomes were reported as comparable to placebo. (Gauthier et al. 2015)

Among the more direct data, the drug was associated with better scores on cognitive measures in a neurodegenerative condition. The important nuance is that standardized mean differences describe group-level shifts, not a guarantee of noticeable improvement for an individual—and the durability of effects beyond treatment cycles is still debated.

Vascular dementia & cognitive impairment

In vascular dementia (and broader vascular cognitive impairment), evidence syntheses tend to be more cautious. A Cochrane review of Cerebrolysin for vascular dementia describes the drug and typical cyclic dosing patterns, and concludes that evidence quality is often low/very low due to risk of bias, indirectness, and imprecision.

Still, within subgroup analyses it reports some short-term benefits on cognitive measures in specific trials—for example, a mean difference on MMSE of +0.96 (95% CI 0.12–1.80, p = 0.03) in one short-term study, and an ADAS-cog+ mean difference of −2.38 (95% CI −4.18 to −0.58, p = 0.01) in another. Safety meta-analysis in the review suggested no clear difference in non-serious adverse events overall (RR 0.91, 95% CI 0.29–2.85, p = 0.87), though serious adverse event data were sparse. (Cui et al. 2019)

A much newer 2025 systematic review/meta-analysis of vascular cognitive impairment interventions (spanning many treatments) reported that, for vascular dementia, Cerebrolysin had a small pooled cognitive effect size (Cohen’s d 0.35, 95% CI 0.03–0.52) across two RCTs (N = 173) over about 4 weeks, with low GRADE certainty. (Masserini et al. 2025)

Prevention or cure?

The most “nootropic-adjacent” claim is whether Cerebrolysin can slow progression from mild cognitive impairment (MCI) toward dementia. A prospective comparative study in first-degree relatives of Alzheimer’s patients with amnestic-type MCI followed participants over ~30 months: 46 received annual Cerebrolysin courses and 42 were untreated controls.

The authors report that by clinician global impression (CGI-I), 95.7% of treated participants achieved “pronounced or moderate improvement” by the end of the third course, and—most strikingly—no treated participants converted to dementia during the 2.5-year observation, while the control group had an annual conversion rate of 9.5%. (Selezneva & Gavrilova 2023)

This is provocative, but interpretation should be conservative: the design described in the abstract is not a large, placebo-controlled, blinded RCT, and dementia conversion is highly sensitive to baseline differences and diagnostic thresholds. Still, it is exactly the kind of study that motivates better-controlled prevention trials.

Perioperative cognition

Cerebrolysin has also been explored for postoperative cognitive outcomes and delirium risk—another setting where “brain under stress” is the target. In a 2025 study of elective coronary artery bypass grafting (CABG), adults were divided into Cerebrolysin (50 mL preoperatively and for 4 postoperative days; n=29) vs control (n=26).

Delirium occurred in 0 treated patients versus 3 control cases (reported as ~11.5% of the control group), though the difference was not statistically significant. On the Montreal Cognitive Assessment (MoCA), the groups were broadly similar pre- and post-operatively, but there was a significant group difference on the second assessment: median MoCA 24 in the Cerebrolysin group vs 27 in controls (p = 0.0083). The authors interpret the overall pattern as “cognitive status maintained” and argue the delirium signal warrants larger studies. (Stadnik et al. 2025)

This illustrates an underappreciated point: “cognitive enhancing” effects are not guaranteed even when a drug is neuroprotective in theory. In small samples, timing and measurement noise can swamp subtle benefits.

Cerebrolysin as a nootropic

Since the definition of a nootropic is in improving cognition in healthy people, the current clinical literature does not support that conclusion, largely because it has not been adequately tested in that population.

Where Cerebrolysin does show repeatable signals is in neurological recovery and impaired cognition—stroke and TBI rehabilitation outcomes, and symptomatic measures in dementias—often with small to modest effect sizes and meaningful uncertainty about durability and real-world significance.

Cerebrolysin is better described as a neurorestorative / neurorehabilitation adjunct than a classic cognitive enhancer. The most consistent benefits appear early (e.g., NIHSS changes post-stroke), while longer-term functional independence outcomes are less consistently improved across studies. (Patel et al. 2025; Khasanova & Kalinin 2023)

References

Patel PN, et al. Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials. (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12465088/

Khasanova DR, Kalinin MN. Cerebrolysin as an Early Add-on to Reperfusion Therapy in Acute Ischemic Stroke: The CEREHETIS Randomized Clinical Trial. (2023). https://pmc.ncbi.nlm.nih.gov/articles/PMC10041692/

Kalinin MN, et al. Cerebrolysin, hemorrhagic transformation, and anticoagulation timing after reperfusion therapy in stroke: post hoc secondary analysis of the CEREHETIS trial. (2025). https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1725255/full

Mureșanu DF, et al. Role and Impact of Cerebrolysin for Ischemic Stroke Care. (2022). https://www.mdpi.com/2077-0383/11/5/1273

Jarosz K, et al. Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis. (2023). https://doi.org/10.3390/brainsci13030507

Gauthier S, et al. Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. (2015). https://pubmed.ncbi.nlm.nih.gov/25832905/

Cui S, et al. Cerebrolysin for vascular dementia. (2019). https://pmc.ncbi.nlm.nih.gov/articles/PMC6844361/

Masserini F, et al. Therapeutic strategies in vascular cognitive impairment: A systematic review and meta-analysis. (2025). https://doi.org/10.1002/alz.70840

Selezneva ND, Gavrilova SI. [Cerebrolysin Treatment Reduces the Risk of Mild Cognitive Decline to Dementia in 1st-Degree Relatives of Alzheimer’s Patients: A Prospective Comparative Study]. (2023). https://pubmed.ncbi.nlm.nih.gov/37655416/

Stadnik A, et al. Effect of Cerebrolysin on Cognitive Function and Delirium in Coronary Artery Bypass Graft Patients. (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12083191/